

Synthesis of New Quinolone Derivatives Linked to Benzothiazole or Benzoxazole Moieties as Anticancer and Anti-Oxidant Agents

Mohamed A Abdelgawad^{1,2*}, Phoebe F Lamie^{1*} and Osama M Ahmed³

¹Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt

²Pharmaceutical Chemistry Department, College of Pharmacy, Al Jouf University, Sakaka, Al Jouf, Saudi Arabia

³Zoology Department, Faculty of Science, Beni-Suef University, Beni Suef, Egypt

Abstract

A new series of substituted quinolones linked to benzothiazole and/or benzoxazole moieties 5a-l was synthesized. 6-Benzoxazol-2-yl/benzothiazol-2-yl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl esters 3a&b were reacted with hydrazine to give the hydrazide derivatives 4a&b and finally, 4a&b were reacted with different aromatic aldehydes giving the target compounds 5a-l. The benzylidene derivatives 5a-l were screened for their cytotoxic activities against breast carcinoma cell lines (MCF-7) and anti-oxidant properties. All the tested compounds 5a-l showed from high to moderate activity as anticancer and anti-oxidant agents. Compounds 5h and 5l showed the highest cytotoxic activity against MCF-7 (IC_{50} : 0.058 and 0.052 μ M, respectively) than 4-(benzothiazol-2-yl) aniline the reference drug (IC_{50} : 0.065 μ M). Moreover, compounds 5e, 5g and 5h showed the highest anti-oxidant activity. The structure of the compounds 5a-l was confirmed using IR, ¹H NMR, mass spectroscopy and elemental analysis.

Keywords: Quinolones; Benzothiazoles; Benzoxazoles; Anti-oxidant activity; Anticancer effect

Introduction

The cytotoxic activity of quinolone derivatives has become the source of new anticancer agents, which might also help addressing side-toxicity and resistance [1]. Moreover, the quinolone ring is considered an important structural unit in many anti-oxidant agents [2]. New synthesized 4-arylchalcogenyl-7-chloroquinolones were screened *in vitro* for antioxidant activity by previous publication which demonstrated that compound presented a potent antioxidant effect [3].

Quinolones were used especially as radicals scavenger like quercetol (A) or coumestrol (B) and the copper or iron chelating molecules such as clioquinol (C) [4,5]. Moreover, quinolone containing hydroxyl group compounds exhibited antiradical activity against DPPH radical and anion superoxide tests activity [6].

On the other hand, benzothiazoles showed potent scavenging activities against DPPH radical and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (D) radicals had reducing power, and strong inhibitory capacity on lipid peroxidation. Also, benzothiazoles or benzoxazoles containing compounds were found to be cytotoxic against CNS cancer cell line SNB-75 [7]. Moreover, 4-(benzothiazol-2-yl) aniline (Eb) showed a promising cytotoxic activity against breast, ovarian, lung and renal cell lines [8-10]. Activity was partially retained in benzoxazole analogue Ea [8] (Figure 1). Compounds of thiol and aminothiols derived from benzothiazoles showed an promising anti-oxidant property [11].

Benzothiazoles and benzoxazoles containing compounds were showed anticancer activity against various cell lines [12,13]. New synthesized compounds containing benzothiazoles or benzoxazoles linked to quinolone showed anticancer and antimicrobial activities [14,15].

According to the aforementioned facts and as a continuation of our previous studies in the field of anticancer screening and anti-oxidant evaluation, [16-19] we attempt to design novel quinolone derivatives through:

- Substitution at quinolone nucleus with benzothiazole and

benzoxazole rings (which have antioxidant or anticancer activity) at 6 position of quinolone.

- Maintain the main structure which responsible for receptor coupling of quinolone.
- Substitution of carboxyl group at 3-position by substituted phenylhydrazine to increase its lipophilicity.
- Over all incorporation of benzoxazole or benzothiazole and quinolone in one scaffold structure.

All the synthesized compounds were evaluated for their anticancer activity against human breast adenocarcinoma cell line (MCF-7) and antioxidant activity.

Materials and Methods

Chemistry

Melting points were determined on a Graffin apparatus and were uncorrected. Element analyses (C, H, and N) were carried out on Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA) at the Micro analytical unit of Cairo University, Egypt. All compounds were within \pm 0.4% of the theoretical values. IR spectra were determined as KBr discs on Shimadzu IR 435 Spectrophotometer and values were represented in cm^{-1} . ¹H NMR spectra were carried out on a Bruker 400


***Corresponding authors:** Mohamed A Abdelgawad, Pharmaceutical Chemistry Department, College of Pharmacy, Al Jouf University, Sakaka, Al Jouf-2014, Saudi Arabia, E-mail: mohamed.abdelgawad@pharm.bsu.edu.eg

Phoebe F Lamie, Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt, Tel: 002012233214514; E-mail: feby.farag@yahoo.com

Received October 12, 2016; **Accepted** October 24, 2016; **Published** October 27, 2016

Citation: Abdelgawad MA, Lamie PF, Ahmed OM (2016) Synthesis of New Quinolone Derivatives Linked to Benzothiazole or Benzoxazole Moieties as Anticancer and Anti-Oxidant Agents. Med Chem (Los Angeles) 6: 652-657. doi:10.4172/2161-0444.1000410

Copyright: © 2016 Abdelgawad MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



MHz NMR Spectrophotometer in Beni Suf University, Beni Suf, Egypt, using (Bruker, Munich, Germany) in DMSO- d_6 as a solvent, TMS as internal standard and chemical shifts were recorded in ppm on δ scale. Mass spectra were run on Hewlett Packard 5988 Spectrometer, Micro analytical center, Cairo University, Egypt. Progress of the reactions was monitored by TLC using TLC sheets percolated with UV fluorescent silica gel MERCK 60 F 254 that were visualized by UV lamp.

General procedure for the synthesis of 6-(benzo[d]oxazol or thiazol-2-yl)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide 4a&b

To a suspension of compounds 3a&b (0.01 mol) in absolute ethanol (30 mL), hydrazine hydrate 99% (5 g, 0.1 mol) was added. The mixture was heated under reflux for 20 h. The precipitated solid was filtered, dried and crystallized from DMF/ethanol.

6-(Benzo[d]oxazole-2-yl)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (4a): Yield: 53%; yellow crystals ;mp: 390-392°C; IR (cm^{-1}): 3465-3192 (2NH and NH_2), 1661,1613 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 4.65 (s, 2H, NH_2 , D_2O exchangeable), 7.47 (m, 2H, Ar-H), 7.86 (m, 2H, Ar-H), 7.92 (d, 1H, $J = 9.2$ Hz, Ar-H), 8.53 (d, 1H, $J = 7.6$ Hz, Ar-H), 8.82 (s, 1H, Ar-H), 9.04 (s, 1H, Ar-H), 10.63 (s, 1H, CONH, D_2O exchangeable), 13.06 (s, 1H, NH, D_2O exchangeable); MS m/z : 320 [(M) $^+$, 7.98%], 288 [($\text{C}_{17}\text{H}_8\text{N}_2\text{O}_3$) $^+$, 100%]. Anal. Calcd. for $\text{C}_{17}\text{H}_{12}\text{N}_4\text{O}_3$: C, 63.75; H, 3.78; N, 17.49. Found: C, 63.70; H, 3.50; N, 17.20.

6-(Benzo[d]thiazol-2-yl)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (4b): Yield: 53%; yellow crystals; mp: 396-398°C; IR (cm^{-1}): 3422-3176 (2NH and NH_2), 1661,1624 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 4.51 (s, 2H, NH_2 , D_2O exchangeable), 7.49 (m, 1H, Ar-H), 7.57 (m, 1H, Ar-H), 7.84 (d, 1H, $J = 8.4$ Hz, Ar-H), 8.11 (d, 1H, $J = 7.2$ Hz, Ar-H), 8.18 (d, 1H, $J = 7.2$ Hz, Ar-H), 8.40 (d, 1H, $J = 8$ Hz, Ar-H), 8.81 (s, 1H, Ar-H), 8.89 (s, 1H, Ar-H), 10.84 (s, 1H, CONH, D_2O exchangeable), 13.29 (s, 1H, NH, D_2O exchangeable); MS m/z : 336 [(M) $^+$, 20.70%], 57 [(C_4H_9) $^+$, 100%]. Anal. Calcd. For $\text{C}_{17}\text{H}_{12}\text{N}_4\text{O}_2\text{S}$: C, 60.70; H, 3.60; N, 16.66. Found: C, 60.60; H, 3.40; N, 16.50.

General procedure for the synthesis of (ZE)-6-(benzo[d]oxazol or thiazol-2-yl)-N'-substituted benzylidene-4-oxo-1,4-dihydroquinoline-3-carbohydrazide 5a-1

A mixture of 4a&b (0.01 mol) and the appropriate aromatic aldehyde (0.01 mol) in absolute ethanol, catalytic amount of glacial acetic acid was added (0.5 mL). The reaction mixture was heated under reflux for 8-10 h (monitored by TLC). The separated solid was filtered, dried and crystallized from DMF.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-benzylidene-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5a): Yield: 53%; yellow solid; mp: 349-351°C; IR (cm^{-1}): 3439, 3141 (2NH), 3089 (CH aromatic), 1697, 1615 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 7.47 (m, 6H, Ar-H), 7.86 (m, 5H, Ar-H), 8.47 (s, 1H, Ar-H), 8.72 (s, 1H, Ar-H), 8.95 (s, 1H, N=CH), 9.09 (s, 1H, CONH, D_2O exchangeable), 13.26 (s, 1H, NH, D_2O exchangeable); MS m/z : 409 [(M+1) $^+$, 8.18%], 408 [(M) $^+$, 13.48%], 288 [($\text{C}_{17}\text{H}_8\text{N}_2\text{O}_3$) $^+$, 100%]. Anal. Calcd. for $\text{C}_{24}\text{H}_{16}\text{N}_4\text{O}_3$: C, 67.91; H, 3.80; N, 13.20. Found: C, 68.00; H, 3.60; N, 12.90.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-(2-hydroxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5b): Yield: 53%; yellow solid; mp: 350-352°C; IR (cm^{-1}): 3425-3141 (OH and 2NH), 3089 (CH aromatic), 1696, 1609 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 6.95 (m, 2H, Ar-H), 7.47 (m, 4H, Ar-H), 7.96 (m, 4H, Ar-H), 8.69 (s, 1H, Ar-H), 8.95 (s, 1H, Ar-H), 9.08 (s, 1H, N=CH), 9.09 (s, 1H, CONH, D_2O exchangeable), 11.33 (s, 1H, OH, D_2O exchangeable), 13.20 (s, 1H, NH, D_2O exchangeable); MS m/z : 425 [(M+1) $^+$, 3.52%], 424 [(M) $^+$, 5.37%], 80 [($\text{C}_3\text{N}_2\text{O}$) $^+$, 100%]. Anal. Calcd. for $\text{C}_{24}\text{H}_{16}\text{N}_4\text{O}_4$: C, 67.92; H, 3.80; N, 13.20. Found: C, 67.80; H, 3.50; N, 13.00.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-(4-florobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5c): Yield: 53%; yellow solid; mp: 354-356°C; IR (cm^{-1}): 3441, 3141 (2NH), 3088 (CH aromatic), 1696, 1623 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 7.34 (m, 2H, Ar-H), 7.47 (m, 2H, Ar-H), 7.96 (m, 4H, Ar-H), 7.99 (m, 2H, Ar-H), 8.48 (s, 1H, Ar-H), 8.54 (s, 1H, Ar-H), 8.95 (s, 1H, N=CH), 9.09 (s, 1H, CONH, D_2O exchangeable), 13.26 (s, 1H, NH, D_2O exchangeable); MS m/z : 427 [(M+1) $^+$, 21.86%], 426 [(M) $^+$, 29.96%], 79 [(C_5F) $^+$, 100%]. Anal. Calcd. For $\text{C}_{24}\text{H}_{15}\text{FN}_4\text{O}_3$: C, 67.60; H, 3.55; N, 13.14. Found: C, 67.40; H, 3.30; N, 13.10.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-(4-chlorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5d): Yield: 53%; yellow solid; mp: 378-380°C; IR (cm^{-1}): 3430, 3141 (2NH), 3088 (CH aromatic), 1696, 1623 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 7.47 (m, 1H, Ar-H), 7.68 (m, 2H, Ar-H), 7.81 (d, 2H, $J = 8.4$ Hz, Ar-H), 7.87 (m, 3H, Ar-H), 7.93 (m, 2H, Ar-H), 7.97 (s, 1H, Ar-H), 8.48 (s, 1H, Ar-H), 8.95 (s, 1H, N=CH), 9.09 (s, 1H, CONH, D_2O exchangeable), 13.26 (s, 1H, NH, D_2O exchangeable); MS m/z : 443 [(M) $^+$, 6.22%], 80 [($\text{C}_3\text{N}_2\text{O}$) $^+$, 100%]. Anal. Calcd. For $\text{C}_{24}\text{H}_{15}\text{ClN}_4\text{O}_3$: C, 65.09; H, 3.41; N, 12.65. Found: C, 64.80; H, 3.10; N, 12.70.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-(4(dimethylamino)benzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5e): Yield: 53%; orange solid; mp: 354-356°C; IR (cm^{-1}): 3436, 3141 (2NH), 3085 (CH aromatic), 1696, 1600 (2C=O); $^1\text{H NMR}$ (DMSO- d_6) δ ppm 3.6 (s, 6H, 2 NCH_3), 7.55 (m, 6H, Ar-H), 8.26 (m, 6H, Ar-H), 8.39 (s, 1H, CONH, D_2O exchangeable), 8.93 (s, 1H, N=CH), 14.26 (s, 1H, NH, D_2O exchangeable); MS m/z : 451 [(M) $^+$, 9.64%], 80 [($\text{C}_3\text{H}_6\text{N}$) $^+$, 100%]. Anal. Calcd. For $\text{C}_{26}\text{H}_{21}\text{N}_5\text{O}_3$: C, 69.17; H, 4.69; N, 15.51. Found: C, 68.80; H, 4.40; N, 15.50.

(ZE)-6-(Benzo[d]oxazol-2-yl)-N'-(4-nitrobenzylidene)-4-oxo-

1,4-dihydroquinoline-3-carbohydrazide (5f): Yield: 53%; brown solid; mp: 347-349°C; IR (cm⁻¹): 3434, 3141 (2NH), 3089 (CH aromatic), 1694, 1617 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 7.54 (m, 4H, Ar-H), 7.76 (m, 2H, Ar-H), 8.13 (m, 3H, Ar-H), 8.82 (s, 2H, N=CH and CONH, D₂O exchangeable), 8.87 (m, 3H, Ar-H), 11.19 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 454 [(M+1)⁺, 23.62%], 453 [(M)⁺, 40.94%], 61 [(C₅H)⁺, 100%]. Anal. Calcd. For C₂₄H₁₅N₅O₅: C, 63.58; H, 3.33; N, 15.45. Found: C, 63.20; H, 3.00; N, 15.20.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-benzylidene-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5g): Yield: 53%; yellow solid; mp: 396-398°C; IR (cm⁻¹): 3404, 3259 (2NH), 3061 (CH aromatic), 1661, 1622 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 7.45 (m, 4H, Ar-H), 7.56 (m, 2H, Ar-H), 7.78 (m, 2H, Ar-H), 8.16 (m, 2H, Ar-H), 8.79 (s, 2H, Ar-H), 8.80 (s, 1H, N=CH), 8.91 (d, 1H, J= 14.8 Hz, Ar-H), 10.87 (s, 1H, CONH, D₂O exchangeable), 14.02 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 425 [(M+1)⁺, 43.94%], 424 [(M)⁺, 53.03%], 55 [(C₅H)⁺, 100%]. Anal. Calcd. For C₂₄H₁₆N₄O₅S: C, 67.91; H, 3.80; N, 13.20. Found: C, 67.70; H, 3.80; N, 13.10.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-(2-hydroxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5h): Yield: 48%; yellow solid; mp: 362-364°C; IR (cm⁻¹): 3400-3166 (OH and 2NH), 3057 (CH aromatic), 1658, 1617 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 6.96 (m, 2H, Ar-H), 7.54 (m, 4H, Ar-H), 7.84 (m, 1H, Ar-H), 8.09 (d, 2H, J= 1.2 Hz, Ar-H), 8.40 (m, 1H, A-H), 8.62 (s, 1H, N=CH), 8.90 (s, 2H, Ar-H), 10.69 (s, 1H, CONH, D₂O exchangeable), 11.46 (s, 1H, OH, D₂O exchangeable), 13.78 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 441 [(M+1)⁺, 61.22%], 440 [(M)⁺, 56.12%], 135 [(C₇H₇N₂O)⁺, 100%]. Anal. Calcd. For C₂₄H₁₆N₄O₅S: C, 65.44; H, 3.66; N, 12.72. Found: C, 65.60; H, 3.40; N, 12.50.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-(4-fluorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5i): Yield: 48%; yellow solid; mp: 395-397°C; IR (cm⁻¹): 3426, 3262 (2NH), 3063 (CH aromatic), 1661, 1623 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 7.54 (m, 4H, Ar-H), 8.08 (m, 2H, Ar-H), 8.13 (m, 3H, Ar-H), 8.84 (m, 2H, Ar-H), 9.60 (s, 1H, N=CH), 9.61 (s, 1H, Ar-H), 11.00 (s, 1H, CONH, D₂O exchangeable), 13.26 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 443 [(M+1)⁺, 3.21%], 442 [(M)⁺, 21.57%], 69 [(C₅H₅)⁺, 100%]. Anal. Calcd. For C₂₄H₁₅FN₄O₅S: C, 65.15; H, 3.42; N, 12.66. Found: C, 64.90; H, 3.20; N, 12.70.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-(4-chlorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5j): Yield: 48%; yellow solid; mp: 398-400°C; IR (cm⁻¹): 3432, 3209 (2NH), 3047 (CH aromatic), 1660, 1621 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 7.53 (m, 4H, Ar-H), 7.77 (m, 3H, Ar-H), 7.79 (m, 4H, Ar-H), 8.38 (s, 1H, Ar-H), 8.91 (s, 1H, N=CH), 10.08 (s, 1H, CONH, D₂O exchangeable), 14.41 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 459 [(M)⁺, 19.07%], 458 [(M-H)⁺, 17.53%], 54 [(C₄H₆)⁺, 100%]. Anal. Calcd. For C₂₄H₁₅ClN₄O₅S: C, 62.81; H, 3.29; N, 12.21. Found: C, 62.60; H, 3.40; N, 12.10.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-(4-(dimethylamino)benzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5k): Yield: 48%; orange solid; mp: 378-380°C; IR (cm⁻¹): 3420, 3263 (2NH), 3065 (CH aromatic), 1661, 1622 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 3.45 (s, 6H, 2CH₃), 7.00 (d, 2H, J= 4.4 Hz, Ar-H), 7.49 (m, 4H, Ar-H), 7.54 (m, 2H, Ar-H), 8.16 (d, 1H, J= 7.6 HZ, Ar-H), 8.34 (d, 1H, J= 8.4 Hz, Ar-H), 8.81 (s, 1H, Ar-H), 8.90 (s, 1H, N=CH), 8.92 (s, 1H, Ar-H), 10.96 (s, 1H, CONH, D₂O exchangeable), 14.22 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 468 [(M+1)⁺, 25%], 467 [(M)⁺, 7.41%], 217 [(C₁₂H₁₅N₃O)⁺, 100%]. Anal. Calcd. For C₂₆H₂₁N₅O₅S: C, 66.79; H, 4.53; N, 14.98. Found: C, 66.90; H, 4.40; N, 14.90.

(ZE)6-(Benzo[d]thiazol-2-yl)-N'-(4-nitrobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (5l): Yield: 48%; brown solid; mp: 356-358°C; IR (cm⁻¹): 3419, 3212 (2NH), 3160, 3053 (CH aromatic), 1664, 1623 (2C=O); ¹H NMR (DMSO-*d*₆) δ ppm 7.48 (m, 3H, Ar-H), 8.16 (m, 7H, Ar-H), 8.41 (s, 1H, Ar-H), 8.92 (s, 1H, N=CH), 8.93 (s, 2H, Ar-H and CONH, D₂O exchangeable), 14.62 (s, 1H, NH, D₂O exchangeable); MS *m/z*: 470 [(M+1)⁺, 23.77%], 469 [(M)⁺, 60.66%], 428 [(C₂₃H₁₄N₃O₄S)⁺, 100%]. Anal. Calcd. For C₂₄H₁₅N₅O₄S: C, 61.40; H, 3.22; N, 14.92. Found: C, 61.20; H, 3.50; N, 14.70.

Biological Evaluation

Anticancer screening

Human tumor cell lines: Breast carcinoma cell lines (MCF-7) used in this study were obtained from the American Type Culture Collection (ATCC, Minisota, USA) through the Tissue Culture Unit, the Egyptian Organization for Biological Products and Vaccines, Vaccera, 51 Wezaret El Zeraa St., Agouza, Giza, Egypt. The tumor cell lines were maintained at Center for Genetic Engineering, Al-Azhar University, Cairo, Egypt by serial sub-culturing.

Chemicals

Dimethylsulphoxide (DMSO), Dulbecco's Modified Eagle Medium (DMEM), trypan blue, Fetal Bovine Serum, Penicillin/ Streptomycin antibiotic and Trypsin- EDTA Sigma Aldrich Chemical Co., St. Louis, Mo, USA. Tris buffer was obtained from Applchem, Germany. All chemicals and reagents used in this study are of highest analytical grade.

Methods

Preparation of test compounds

The tested derivatives **5a-l** were prepared by dissolving in dimethylsulfoxide (DMSO) and the prepared stock was stored at -20°C. Different concentrations of the compounds 0, 6.25, 12.5, 25, 50 and 100 µg/ml in culture medium were used.

Preparatory steps prior to cytotoxicity investigation

Maintenance of the breast carcinoma cell lines (MCF-7) in the laboratory, cryopreservation of cells, collection of cells by trypsinization and determination and counting of viable cells are performed according to the reported methods [20,21].

Determination of potential cytotoxicity of drug on human cancer cell line

The cytotoxicity was carried out using Sulphorhodamine-B (SRB) assay following the reported method [22] SRB is a bright pink aminoxanthrene dye with two sulphonic groups. It is a protein stain that binds to the amino groups of intracellular proteins under mildly acidic conditions to provide a sensitive index of cellular protein content.

Cells of MCF-7 cell lines are seeded in 96 well microliter plates at a concentration of 1000-2000 cells/well, 100 µl/well. After 24 h, cells will be incubated for 72 h with various concentrations of drugs (0, 6.25, 12.5, 25, 50 and 100 µg/ml). Dulbecco's Modified Eagle Medium (DMEM) with 10% foetal calf serum, sodium pyruvate, 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C and 5% CO₂, was used as culture medium. At the end of the incubation, the medium is discarded. The cells are fixed with 150 µl cold trichloroacetic acid 10% final concentration for 1 hour at 4°C. The plates were washed with distilled water using (automatic washer Tecan, Germany) and stained

with 50 μ l 0.4% SRB dissolved in 1% acetic acid for 30 minutes at room temperature in dark. The plates were washed with 1% acetic acid to remove unbound dye and air-dried (24 h). The dye was solubilized with 150 μ l/well of 10 mM Tris base (PH 7.4) for 5 min on a shaker at 1600 rpm. The optical density (OD) of each well will be measured spectrophotometrically at 490 nm with an ELISA microplate reader. The mean background absorbance was automatically subtracted and mean values of each derivative and 4-(benzothiazol-2-yl) aniline (reference drug) concentration was calculated. The experiment was repeated three times. The percentage of cell survival was calculated by using formula, surviving percent = $[\text{OD}(\text{treated cells})/\text{OD}(\text{control cells})] \times 100$. The IC_{50} values (the concentrations of derivatives required to produce 50% inhibition of cell growth) were also calculated using linear trend linear equation.

Anti-oxidant assay

DPPH radical scavenging activity: The effect of the synthesized organic compounds on DPPH radical was estimated using the reported methods [23,24] with some modifications. A solution of 200 μ mol DPPH in ethanol was prepared and 100 μ l of this solution was mixed with 0.9 ml of varying concentrations of the synthesized derivatives (dissolved in ethanol) to reach a final concentration of 0.25, 0.5 and 1 mg/ml. The reaction mixture was vortexed and left in the dark for 30 min (room temperature). The color became light yellow from deep violet and the absorbance of the mixture was determined at 570 nm. The control was prepared by using adding 100 μ l DPPH to 0.9 ml ethanol solution.

$$\text{DPPH radical scavenging activity (\%)} = \frac{1}{2} \left[\frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \right] \times 100$$

Where A_{control} is the absorbance of DPPH radical + ethanol and A_{sample} is the absorbance of DPPH radical + sample of derivative compound dissolved in ethanol.

Results and Discussion

Chemistry

In this work, the synthesis of different Schiff bases at C-3 of quinolone moiety was described. Biologically important benzoxazoles and benzothiazoles were merged with quinolone nucleus. 6-Benzoxazole/benzothiazol-2-yl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl esters **3a&b** were employed as the starting materials. They were synthesized following the precautions of their reported method [14]. Direct conversion of **3a&b** into hydrazide derivatives **4a&b** was achieved in good yield by the treatment of **3a&b** with hydrazine hydrate 99%. Several solvents were carried out to prepare these intermediates **4a&b** such as absolute ethanol, glacial acetic acid and dioxane. Absolute ethanol was the solvent of choice since it gave more pure products (using: TLC) as well as higher yields (Scheme 1). The structure of compounds **4a&b** was established on the basis of IR, ^1H NMR, mass spectral data and elemental analysis. IR spectra of **4a&b** revealed the appearance of new absorption bands at 3465-3176 cm^{-1} due to 2NH and NH_2 groups.

The structure of the compounds **4a&b** was confirmed by ^1H NMR which was performed in DMSO as a solvent, appearance of D_2O exchangeable singlet signal at δ 4.51 and 4.65 ppm indicated NH_2 protons, beside the appearance of another exchangeable singlet signal corresponding to CONH proton at δ 10.63 and 10.84 ppm, respectively. Moreover, mass spectra of **4a&b** showed molecular ion peaks at m/z 320 and 336, sequentially. Heating compounds **4a&b** for 8-10 hours with different aromatic aldehydes in absolute ethanol containing

catalytic amount of glacial acetic acid led to the formation of **5a-l**. The formation of the target Schiff bases **5a-l** was substantiated on basis of spectral data and elemental analysis (see Experimental Section).

^1H NMR spectra of compounds **5a-l** showed disappearance of D_2O exchangeable singlet signal of NH_2 protons of the parent hydrazide derivatives **4a&b** and the appearance of new singlet signal due to azomethine proton ($\text{N}=\text{CH}$) at δ 8.82-9.08 ppm in benzoxazole derivatives **5a-f** or at δ 8.80-9.60 ppm for benzothiazole derivatives **5g-l**.

Additionally, the mass spectrum of compound **5d** revealed molecular ion peaks at m/z 443 and 445 corresponding to $(\text{M})^+$ and $(\text{M}+2)^+$, respectively in ratio of 3:1 (Cl pattern). The reactivity of the applied aromatic aldehydes was appeared in parallel manner with the yield of the resulting targets **5a-l**, which ranged between 45% up to 79% starting from benzaldehyde to 4-nitrobenzaldehyde in both benzoxazole and benzothiazole derivatives.

Anticancer activity

The data showing the anti-proliferative effects of the tested derivatives on breast carcinoma cell lines (MCF-7) are illustrated in Figures 1 and 2. All derivatives from **5a** to **5l** produced a marked gradual decrease in the survival percent of MCF-7 as the dose of derivatives increased from 0 to 100 μ g/ml. Based on the values of IC_{50} , the derivatives are arranged according to their tumor cytotoxic potencies in the following order: derivatives **5l**, **5h**, **5g**, **5k**, **5e**, **5f**, **5a**, **5i**, **5d**, **5j**, **5c** and **5a** recording IC_{50} of 40.783, 45.461, 48.953, 50.627, 52.138, 53.665, 54.163, 55.344, 57.462, 58.452, 69.214 and 82.300 μ g/ml, respectively Scheme 2. Thus, derivative **5l** produced the most potent tumor cytotoxic efficacy, while derivative **5a** followed by derivative **5c** are the least potent (Figure 2 and Table 1).

Anti-oxidant activity

The antioxidant capacity was evaluated by detection of DPPH radical scavenging activity. Different concentrations of derivatives were tested. All tested derivatives had marked antioxidant activity. At






Figure 2: Chemical structure of the target compounds **5a-l**.



lowest dose, 0.25 mg/ml, derivative **5a** followed by **5e** seemed to have the most potent DPPH radical scavenging activity percent recording 26.33 and 21.58%, respectively. At medium dose (0.5 mg/ml) and high dose (1 mg/ml), derivatives **5e**, **5g** and **5h** were the most efficient in having antioxidant activity. Derivative **5c** had no antioxidant activity at high dose although it had marked efficacy at low and medium doses. Moreover, while the antioxidant activity of **5a**, **5b** and **5l** was more or less unchanged as the dose increased from 0.5 to 1 mg/ml, it was more potentiated for derivatives **5d**, **5f**, **5g**, **5h**, **5i**, **5j** and **5k** (Table 2).

Conclusion

The synthesized derivatives exhibited various degrees of cytotoxic effects on breast carcinoma cell line (MCF-7) *in vitro*. Comparing the new compounds with 4-(benzothiazol-2-yl)aniline – known with its cytotoxic activity- which has IC_{50} 0.065 μ M, we observed that: (ZE)-6-(benzo[d]thiazol-2-yl)-N'-(4-nitrobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (**5l**) and (ZE)-6-(Benzo[d]thiazol-

2-yl)-N'-(2-hydroxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (**5h**) seemed to have the most potent antitumor action (IC_{50} : 0.052 μ M and 0.058 μ M, respectively), in addition to five new compounds **5e**, **5f**, **5g**, **5i** and **5k** showed good activity with IC_{50} between 0.072 μ M and 0.099 μ M. Only five compounds (**5a**, **5b**, **5c**, **5d**, **5j**) exhibit moderate activity, with IC_{50} in the range of 0.10 μ M and 0.20w μ M. On the other hand, (ZE)-6-(benzo[d]oxazol-2-yl)-N'-(4-(dimethylamino)benzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (**5e**), (ZE)-6-(benzo[d]thiazol-2-yl)-N'-(2-hydroxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (**5h**) have the most efficient antioxidant activity as indicated by the results of DPPH radical scavenging capacity. Finally, it was found that compound **5h** bearing 4-hydroxyphenyl moiety and benzothiazole nucleus has dual anticancer and anti-oxidant activity and need further investigations.

Conflict of Interest

The authors declared that there is no conflict of interest.

Compound No.	IC_{50} (μ M)
5a	0.2
5b	0.117
5c	0.15
5d	0.106
5e	0.078
5f	0.085
5g	0.072
5h	0.058
5i	0.099
5j	0.104
5k	0.074
5l	0.052
4-(benzothiazol-2-yl)aniline (standard)	0.065

Table 1: IC_{50} of the test compounds (**5a-l**) against breast cancer (MCF-7).

Derivatives	0.25 mg/ml	0.5 mg/ml	1 mg/ml
5a	26.33	12.16	13.50
5b	15.58	10.75	11.50
5c	10.25	20.00	0.00
5d	15.75	13.75	18.33
5e	21.58	31.84	39.75
5f	3.58	2.5	9.83
5g	12.97	25.52	40.83
5h	12.97	25.52	40.82
5i	13.64	19.39	31.65
5j	8.92	6.58	11.75
5k	11.59	20.63	27.28
5l	12.33	14.83	15.92

Table 2: DPPH radical scavenging activity (%) of derivative compounds (**5a-l**) at various concentrations.

References

1. Sissi C, Palumbo M (2003) The quinolone family: from antibacterial to anticancer agents. *Curr Med Chem Anticancer agents* 3: 439-450.
2. Orhan PM, Tekiner B, Suzen S (2013) Recent studies of antioxidant quinoline derivatives. *Mini Rev Med Chem* 13: 365-372.
3. Lucielli S, Aline IV, Natália S, Bruna SG, Micheli RC, et al. (2013) Synthesis and antioxidant properties of novel quinoline-chalcogenium compounds. *Tetrahed Lett* 54: 40-44.
4. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI (1989) Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. *Biochem Pharmacol* 38: 1763-1769.
5. Mitchell JH, Gardner PT, McPhail DB, Morrice PC, Collins AR, et al. (1998) Antioxidant efficacy of phytoestrogens in chemical and biological model systems *Arch. Biochem Biophys* 36: 142-148.
6. Mustapha B, Lhassane I, Isabelle T, Laurence N, Marc P, et al. (2011) Pharmacophore Modelling and Synthesis of Quinoline-3-Carbohydrazide as Antioxidants. *Int J med Chem* 592879.
7. Karali N, Güzel O, Ozsoy N, Ozbey S, Salman A (2010) Synthesis of new spiroindolinones incorporating a benzothiazole moiety as antioxidant agents. *Eur J med Chem* 45: 1068-1077.
8. Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, et al. (1998) 2-(4-Aminophenyl) benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. *British Journal of Cancer* 77: 745-752.
9. Chua MS, Shi DF, Wrigley S, Bradshaw TD, Hutchinson I, et al. (1999) Synthesis of 2-(4-acylamino-phenyl) benzothiazoles and investigations into the role of acetylation in the antitumour activities of the parent amines. *J Med Chem* 42: 381-392.
10. Bradshaw TD, Stevens MFG, Westwell AD (2001) The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl) benzothiazole (DF 203) and related compounds. *Curr Med Chem* 8: 203-210.
11. Cressier D, Prouillac C, Hernandez P, Amourette C, Diserbo M, et al. (2009) Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles. *Bioorg Med Chem* 17: 5275-5284.
12. Kok S, Gambari R, Chui CH, Yuen MC, Lin E, et al. (2008) Synthesis and anticancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. *Bioorg Med Chem* 16: 3626-3631.
13. Rosanna C, Maria L, Calabrò NM, Aaron DS, Moshin A, et al. (2012) Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. *Med Chem Res* 21: 2644-2651.
14. Mohamed AS, Ossama MB, Aliaa MK, Mohamd AA (2008) Synthesis and screening of quinolone antibiotic isosteres. *J Chem Res* 715-718.
15. Xuan HS, Zhao W, Yong X, Ting HY, Mei D, et al. (2012) Synthesis and Biological Evaluation of Novel Benzothiazole-2-thiol Derivatives as Potential Anticancer Agents. *Molecules* 17: 3933-3944.
16. Phoebe FL (2014) Synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine and their tricyclic derivatives. *Int J Pharm Sci Rev Res* 24(2): 208-214.
17. Manal MK, Sameha MR, Eman KAA, Mohamed AAG, Phoebe FL (2013) Design, synthesis and cytotoxic activity of some novel compounds containing pyrazolo[3,4-d]pyrimidine nucleus. *J Chem Sci* 125: 1029-1043.
18. Phoebe FL, John NP, Ahmed OE, Lucie R, Jiri G (2015) Design, synthesis and evaluation of novel phthalimide derivatives as in vitro anti-microbial, anti-oxidant and anti-inflammatory agents. *Molecules* 20: 16620-16642.
19. Phoebe FL, Waleed AMA, Vaclav B, Lucie R (2016) Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study. *E J Med Chem* 123: 803-813.
20. Abdelgawad MA, Abdellatif KRA, Ahmed OM (2014) Design, Synthesis and Anticancer Screening of Novel Pyrazole Derivatives Linking to Benzimidazole, Benzoxazole and Benzothiazole. *Med Chem S* 1: 1-7.
21. Ahmed SA, Ahmed OM, Abdou OA (2014) Synthesis and anti-tumor activities of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives. *Eur J Chem* 2: 334-338.
22. Vichai V, Kirtikar K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protoc* 1: 1112-1116.
23. Kumar A, Suchetha KN, Bhargavan D (2012) Evaluation of in vitro antioxidant potential of ethanolic extract from the leaves of *Achyranthesaspera*. *Asian J Pharm Clin Res* 5: 146-148.
24. Ahmed SA, Ahmed OM, Elgendy HS (2014) Novel Synthesis of Puriensanalougues and Thieno[2,3-b] pyridine derivatives with anticancer and antioxidant activity. *J Pharm Res* 8: 1303-1313.